cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Bright Green Corp
4 own
2 watching
Current Price
$0.22
$-0.01
(-3.11%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
31.37M
52-Week High
52-Week High
1.81000
52-Week Low
52-Week Low
0.15000
Average Volume
Average Volume
0.24M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization31.37M
icon52-Week High1.81000
icon52-Week Low0.15000
iconAverage Volume0.24M
iconDividend Yield--
iconP/E Ratio--
What does the Bright Green Corp do?
Bright Green’s mission is to be the premier federally-authorized provider of cannabis, cannabis-related products, and other legal medicinal plant-based therapies, manufactured in exact formulations for research and pharmaceutical applications, as well as being an active ingredient to consumer-based solutions. The Company, through legal partnerships with state and federal agencies, can operate at scale in a manner unprecedented in this emerging market, addressing compliance, security and integrity. Our vision is to improve the quality of life across a broad spectrum of demographics through the opportunities presented by medicinal applications of plant-based therapies, particularly cannabis and cannabis-derived products. We are a first-mover in the U.S. federally-licensed cannabis space. We are one of a few companies who have received conditional approval based on already agreed terms from the U.S. Drug Enforcement Administration (the “DEA”) to produce federally legal cannabis, and have entered into a Memorandum of Agreement (“MOA”) with the DEA which permits us to proceed towards a Federal Registration for the Bulk Manufacturing of cannabis under DEA Document Control Number W20078135E. Unlike state-licensed cannabis companies that engage in commercial sales to consumers, and whose businesses are legal under state law but not federal law, we will operate legally under all applicable laws and be authorized by the federal government to sell cannabis commercially for research and manufacturing purposes, export cannabis for international cannabis research purposes, and sell cannabis to DEA-registered pharmaceutical companies for the production of medical cannabis products and preparations, subject to final registration and licensure with the DEA as set forth in the MOA. We plan to focus on the development of cannabis strains and sales of products with high contents of CBN (cannabinol) and CBG (cannabigerol). If and when permitted under federal law, we also plan to sell cannabis-derived CBN and CBG to consumers. Because cannabis is a Schedule I Controlled Substance in the U.S., it has been historically under-researched. Though the majority of Americans live in states where cannabis is now legal in some form, the full potential of the cannabis plant for medicinal use remains understudied due to limited access to federally-approved cannabis. The DEA recently issued a call for more cannabis research supply based on the increased demand for cannabis research in the U.S. As described herein, we received conditional approval from the DEA based on the agreed-upon terms set forth in the MOA. Final approval from the DEA is conditioned on, among other things, completed construction of manufacturing and production facilities and systems. In May 2021, BGC entered into the MOA with the DEA to grow cannabis for federally sanctioned research. Final registration is anticipated in June 2022, and is contingent upon completion of construction and a successful inspection by the DEA of BGC’s facilities. Additionally, BGC must comply with the terms agreed in the MOA which include: submitting an Individual Procurement Quota on or before April 1 of each year utilizing DEA Form 250; submitting an Individual Manufacturing Quota on or before May 1 of each year utilizing DEA Form 189; collecting samples of cannabis and distributing them to DEA-registered analytical laboratories for chemical analysis during the pendency of cultivation and prior to the DEA’s taking possession of the cannabis grown; providing the DEA with 15-day advance written notification, via email, of its intent to harvest cannabis; following the DEA’s packaging, labeling, storage and transportation requirements; distributing DEA’s stocks of cannabis to buyers who entered into bona fide supply agreements with the Company; providing the DEA with 15-day advance written notification of its intent to distribute cannabis; invoicing the DEA for harvested cannabis that it intends to sell to the DEA. Following final approval, we will be permitted to cultivate and manufacture cannabis, supply cannabis researchers in the U.S. and globally, and produce cannabis for use in pharmaceutical production of prescription medicines within the U.S. There is no guarantee that we will receive approval from the DEA. Our activities will be legal under federal law, which currently sets BGC apart from all U.S. cannabis companies who are selling products to consumers and patients under state programs. We have assembled an experienced team of medical professionals and researchers, international horticultural growers and experts, and construction and cannabis production professionals, which we believe positions us to become a future industry leader in the production of cannabis. The business address of each Registered Stockholder is c/o Bright Green Corporation, 401 East Las Olas Blvd., Suite 1400, Ft. Lauderdale, FL.
Read More
How much money does Bright Green Corp make?
News & Events about Bright Green Corp.
Globe Newswire
10 months ago
The Company views the development as an additional milestone building on its key strategic achievement in 2023 already including its historic DEA registration and confirmation of its EB-5 program. The Company looks now to produce its first harvest of Botanical Raw Material and Active Pharmaceutical ...
Globe Newswire
10 months ago
NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against RH (NYSE: RH), Hayward Holdings, Inc. (NYSE: HAYW), Bright Green Corporation (NASDAQ: BGXX), and Veradigm, Inc. (NASDAQ: MDRX). Our ...
Globe Newswire
11 months ago
Bright Green, the first publicly traded company in the U.S. to be federally authorized to grow, manufacture and sell cannabis and cannabis-related products for research, pharmaceutical and medical applications, can qualify for the EB-5 program and plans to raise $500 million in new capital The ...
Globe Newswire
11 months ago
Bright Green is now the first publicly traded company, and the largest, in the U.S. to be federally authorized to grow, manufacture and sell cannabis and cannabis-related products for research, pharmaceutical applications and affiliated import and export Company to commence cultivation preparation ...
Globe Newswire
1 year ago
NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against FTX Tokens (CCC: FTT), G-III Apparel Group, Ltd. (NASDAQ: GIII), Bright Green Corporation (NASDAQ: BGXX), and Consensus Cloud ...
Frequently Asked Questions
Frequently Asked Questions
What is Bright Green Corp share price today?
plus_minus_icon
Can Indians buy Bright Green Corp shares?
plus_minus_icon
How can I buy Bright Green Corp shares from India?
plus_minus_icon
Can Fractional shares of Bright Green Corp be purchased?
plus_minus_icon
What are the documents required to start investing in Bright Green Corp stocks?
plus_minus_icon
What is today’s traded volume of Bright Green Corp?
plus_minus_icon
What is today’s market capitalisation of Bright Green Corp?
plus_minus_icon
What is the 52-Week High and Low Range of Bright Green Corp?
plus_minus_icon
What percentage is Bright Green Corp down from its 52-Week High?
plus_minus_icon
What percentage is Bright Green Corp up from its 52-Week Low?
plus_minus_icon
Current Price
$0.22
$-0.01
(-3.11%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00